Niaid-dmid monkeypox vaccine clinical trial - jynneos dose sparing trial
Ended Awarded Last action
- Contract number
- 75N91022F00024
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $18,142,791
Award facts
- Contract value 100% obligated
- $18,142,791.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $1,100,557 | |
| Supplemental Agreement for work within scope | $5,544,628 | |
| Original award | $11,497,606 |
About this award
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc. for a clinical trial of the JYNNEOS monkeypox vaccine to evaluate dose sparing. The total ceiling value of the contract is $18,142,791.00. The contract is a cost-plus-fixed-fee type and does not have a set-aside designation. Leidos Biomedical Research Inc. is a subsidiary of the larger Leidos Holdings, Inc. organization, which has served as a subcontractor on various federal contracts. This award supports NIAID's research efforts related to monkeypox and the development of medical countermeasures against infectious diseases.
Quick answers
Who was awarded contract 75N91022F00024?
75N91022F00024 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2022.
How much is contract 75N91022F00024 worth?
The government has obligated $18,142,791 on 75N91022F00024.
Which agency awarded contract 75N91022F00024?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00024, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00024 an order under another contract?
Yes. 75N91022F00024 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00024 competed?
The extent of competition for 75N91022F00024 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award